Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt No Debt
CLDX's Cash to Debt is ranked higher than
96% of the 940 Companies
in the Global Biotechnology industry.

( Industry Median: 101.30 vs. CLDX: No Debt )
Ranked among companies with meaningful Cash to Debt only.
CLDX' s Cash to Debt Range Over the Past 10 Years
Min: 2.95  Med: 139.03 Max: No Debt
Current: No Debt
Equity to Asset 0.86
CLDX's Equity to Asset is ranked higher than
74% of the 710 Companies
in the Global Biotechnology industry.

( Industry Median: 0.70 vs. CLDX: 0.86 )
Ranked among companies with meaningful Equity to Asset only.
CLDX' s Equity to Asset Range Over the Past 10 Years
Min: -0.32  Med: 0.83 Max: 0.94
Current: 0.86
-0.32
0.94
Interest Coverage No Debt
CLDX's Interest Coverage is ranked higher than
95% of the 375 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. CLDX: No Debt )
Ranked among companies with meaningful Interest Coverage only.
CLDX' s Interest Coverage Range Over the Past 10 Years
Min: N/A  Med: 10000.00 Max: 9999.99
Current: No Debt
N/A
9999.99
F-Score: 4
Z-Score: 2.31
M-Score: -2.71
WACC vs ROIC
28.30%
-1220.84%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -2131.84
CLDX's Operating margin (%) is ranked lower than
83% of the 733 Companies
in the Global Biotechnology industry.

( Industry Median: -72.99 vs. CLDX: -2131.84 )
Ranked among companies with meaningful Operating margin (%) only.
CLDX' s Operating margin (%) Range Over the Past 10 Years
Min: -3414.11  Med: -493.44 Max: -13.79
Current: -2131.84
-3414.11
-13.79
Net-margin (%) -2091.08
CLDX's Net-margin (%) is ranked lower than
83% of the 733 Companies
in the Global Biotechnology industry.

( Industry Median: -74.36 vs. CLDX: -2091.08 )
Ranked among companies with meaningful Net-margin (%) only.
CLDX' s Net-margin (%) Range Over the Past 10 Years
Min: -3292.81  Med: -505.66 Max: -5.41
Current: -2091.08
-3292.81
-5.41
ROE (%) -41.41
CLDX's ROE (%) is ranked lower than
58% of the 861 Companies
in the Global Biotechnology industry.

( Industry Median: -31.54 vs. CLDX: -41.41 )
Ranked among companies with meaningful ROE (%) only.
CLDX' s ROE (%) Range Over the Past 10 Years
Min: -4205.83  Med: -67.06 Max: -3.4
Current: -41.41
-4205.83
-3.4
ROA (%) -36.93
CLDX's ROA (%) is ranked lower than
60% of the 944 Companies
in the Global Biotechnology industry.

( Industry Median: -26.66 vs. CLDX: -36.93 )
Ranked among companies with meaningful ROA (%) only.
CLDX' s ROA (%) Range Over the Past 10 Years
Min: -120  Med: -42.35 Max: -2.02
Current: -36.93
-120
-2.02
ROC (Joel Greenblatt) (%) -1143.38
CLDX's ROC (Joel Greenblatt) (%) is ranked lower than
63% of the 905 Companies
in the Global Biotechnology industry.

( Industry Median: -357.95 vs. CLDX: -1143.38 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
CLDX' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -1156.55  Med: -530.69 Max: -10.72
Current: -1143.38
-1156.55
-10.72
Revenue Growth (3Y)(%) -33.90
CLDX's Revenue Growth (3Y)(%) is ranked lower than
79% of the 491 Companies
in the Global Biotechnology industry.

( Industry Median: 3.30 vs. CLDX: -33.90 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
CLDX' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -67.2  Med: -10.30 Max: 71.9
Current: -33.9
-67.2
71.9
EBITDA Growth (3Y)(%) 10.40
CLDX's EBITDA Growth (3Y)(%) is ranked higher than
66% of the 493 Companies
in the Global Biotechnology industry.

( Industry Median: -0.70 vs. CLDX: 10.40 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
CLDX' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -32.9  Med: -2.10 Max: 22.8
Current: 10.4
-32.9
22.8
EPS Growth (3Y)(%) 8.60
CLDX's EPS Growth (3Y)(%) is ranked higher than
67% of the 499 Companies
in the Global Biotechnology industry.

( Industry Median: -5.10 vs. CLDX: 8.60 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
CLDX' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -71.6  Med: -7.00 Max: 134.8
Current: 8.6
-71.6
134.8
» CLDX's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-08-10)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q2 2015

CLDX Guru Trades in Q2 2015

Murray Stahl 26,335 sh (unchged)
First Eagle Investment 559,542 sh (unchged)
Paul Tudor Jones Sold Out
Joel Greenblatt Sold Out
Columbia Wanger 2,591,703 sh (-7.46%)
» More
Q3 2015

CLDX Guru Trades in Q3 2015

Columbia Wanger 3,109,615 sh (+19.98%)
Murray Stahl 26,335 sh (unchged)
First Eagle Investment 559,542 sh (unchged)
» More
Q4 2015

CLDX Guru Trades in Q4 2015

Paul Tudor Jones 15,857 sh (New)
Columbia Wanger 3,610,008 sh (+16.09%)
First Eagle Investment 579,542 sh (+3.57%)
Murray Stahl 26,335 sh (unchged)
» More
Q1 2016

CLDX Guru Trades in Q1 2016

John Paulson 70,800 sh (New)
Jim Simons 813,331 sh (New)
Paul Tudor Jones 139,437 sh (+779.34%)
First Eagle Investment 629,542 sh (+8.63%)
Murray Stahl 26,335 sh (unchged)
Columbia Wanger 2,976,400 sh (-17.55%)
» More
» Details

Insider Trades

Latest Guru Trades with CLDX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:NAS:FLML, OCSE:ZEAL, ROCO:6453, NAS:IMMU, NAS:MNKD » details
Traded in other countries:TCE1.Germany,
Celldex Therapeutics Inc is a biopharmaceutical company. The Company is engaged in the development, manufacturing and commercialization of immunotherapy technologies for the treatment of cancer and other difficult-to-treat diseases.

Celldex Therapeutics Inc was incorporated in Delaware. The Company is a biopharmaceutical company focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other difficult-to-treat diseases. Its drug candidate, rindopepimut (CDX-110), is an immunotherapeutic vaccine that targets the tumor-specific molecule, epidermal growth factor receptor variant III (EGFRvIII). EGFRvIII is a mutated form of the epidermal growth factor receptor (EGFR) that is only expressed in cancer cells and not in normal tissue and can directly contribute to cancer cell growth. Its other drug candidates include CDX-011 and CDX-1127. CDX-011 is an antibody-drug conjugate (ADC) that consists of a fully-human monoclonal antibody, CR011, linked to a potent cell-killing drug, monomethyl-auristatin E (MMAE). The CR011 antibody specifically targets glycoprotein NMB (GPNMB) that is expressed in a variety of human cancers including breast cancer. In December 2011, it completed enrollment of EMERGE, a randomized Phase 2b study of CDX-011 in patients with heavily pre-treated, advanced, GPNMB-positive breast cancer. It has additional clinical and preclinical programs, including CDX-1401, an APC Targeting Technology program, CDX-301, an immune cell mobilizing agent and dendritic cell growth factor and CDX-1135, a molecule that inhibits a part of the immune system called the complement system. The Company's products are derived from a broad set of complementary technologies which have the ability to utilize the human immune system and enable the creation of therapeutic agents. It is using these technologies to develop targeted immunotherapeutics comprised of antibodies, adjuvants and monotherapies and antibody-drug conjugates that prevent or treat cancer and other diseases that modify undesirable activity by the body's own proteins or cells. A number of its immunotherapeutic and antibody-drug conjugate drug candidates are in various stages of clinical trials. The Company faces competition from pharmaceutical and biotechnology companies both in the United States and abroad which include Arbor Pharmaceutics, Inc., AstraZeneca PLC, Bayer, Celgene Corporation, Eisai Inc., Eli Lilly and Company, Medigene AG, Northwest Biotherapeutics, Inc., Pfizer Inc., and Roche. In the United States, vaccines and immunotherapeutics for human use are subject to The Food and Drug Administration (FDA) approval as 'biologics' under the Public Health Service Act and 'drugs' under the Federal Food, Drug and Cosmetic Act.

Ratios

vs
industry
vs
history
P/B 1.61
CLDX's P/B is ranked higher than
82% of the 1025 Companies
in the Global Biotechnology industry.

( Industry Median: 3.36 vs. CLDX: 1.61 )
Ranked among companies with meaningful P/B only.
CLDX' s P/B Range Over the Past 10 Years
Min: 1.23  Med: 5.19 Max: 50.74
Current: 1.61
1.23
50.74
P/S 66.85
CLDX's P/S is ranked lower than
79% of the 802 Companies
in the Global Biotechnology industry.

( Industry Median: 12.41 vs. CLDX: 66.85 )
Ranked among companies with meaningful P/S only.
CLDX' s P/S Range Over the Past 10 Years
Min: 1.67  Med: 32.87 Max: 975.38
Current: 66.85
1.67
975.38
Current Ratio 10.31
CLDX's Current Ratio is ranked higher than
77% of the 913 Companies
in the Global Biotechnology industry.

( Industry Median: 4.55 vs. CLDX: 10.31 )
Ranked among companies with meaningful Current Ratio only.
CLDX' s Current Ratio Range Over the Past 10 Years
Min: 0.56  Med: 6.63 Max: 17.22
Current: 10.31
0.56
17.22
Quick Ratio 10.31
CLDX's Quick Ratio is ranked higher than
78% of the 913 Companies
in the Global Biotechnology industry.

( Industry Median: 4.27 vs. CLDX: 10.31 )
Ranked among companies with meaningful Quick Ratio only.
CLDX' s Quick Ratio Range Over the Past 10 Years
Min: 0.56  Med: 6.63 Max: 17.22
Current: 10.31
0.56
17.22
Days Sales Outstanding 49.09
CLDX's Days Sales Outstanding is ranked higher than
63% of the 606 Companies
in the Global Biotechnology industry.

( Industry Median: 63.27 vs. CLDX: 49.09 )
Ranked among companies with meaningful Days Sales Outstanding only.
CLDX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 1.43  Med: 13.35 Max: 89.44
Current: 49.09
1.43
89.44

Valuation & Return

vs
industry
vs
history
Price/Net Cash 1.96
CLDX's Price/Net Cash is ranked higher than
87% of the 670 Companies
in the Global Biotechnology industry.

( Industry Median: 5.01 vs. CLDX: 1.96 )
Ranked among companies with meaningful Price/Net Cash only.
CLDX' s Price/Net Cash Range Over the Past 10 Years
Min: 1.76  Med: 7.61 Max: 47.3
Current: 1.96
1.76
47.3
Price/Net Current Asset Value 1.90
CLDX's Price/Net Current Asset Value is ranked higher than
87% of the 783 Companies
in the Global Biotechnology industry.

( Industry Median: 4.96 vs. CLDX: 1.90 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
CLDX' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 1.7  Med: 6.88 Max: 1163
Current: 1.9
1.7
1163
Price/Tangible Book 1.80
CLDX's Price/Tangible Book is ranked higher than
81% of the 949 Companies
in the Global Biotechnology industry.

( Industry Median: 3.90 vs. CLDX: 1.80 )
Ranked among companies with meaningful Price/Tangible Book only.
CLDX' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.62  Med: 6.15 Max: 54.69
Current: 1.8
1.62
54.69
Price/Median PS Value 2.04
CLDX's Price/Median PS Value is ranked lower than
82% of the 726 Companies
in the Global Biotechnology industry.

( Industry Median: 0.93 vs. CLDX: 2.04 )
Ranked among companies with meaningful Price/Median PS Value only.
CLDX' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.05  Med: 0.99 Max: 38.39
Current: 2.04
0.05
38.39
Earnings Yield (Greenblatt) (%) -81.63
CLDX's Earnings Yield (Greenblatt) (%) is ranked lower than
91% of the 1090 Companies
in the Global Biotechnology industry.

( Industry Median: -9.50 vs. CLDX: -81.63 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
CLDX' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -460.4  Med: 391.85 Max: 1732
Current: -81.63
-460.4
1732

More Statistics

Revenue (TTM) (Mil) $6.30
EPS (TTM) $ -1.33
Beta3.56
Short Percentage of Float30.81%
52-Week Range $2.96 - 29.94
Shares Outstanding (Mil)98.72

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 4 3 43
EPS ($) -1.34 -1.39 -1.34
EPS without NRI ($) -1.34 -1.39 -1.34
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
» More Articles for CLDX

Headlines

Articles On GuruFocus.com
Cantor Fitzgerald and Brean Capital Positive on Celldex Therapeutics Following Positive Data For Bra Jun 01 2015 
Monday Morning Pre-Market Insights: Celldex Therapeutics, Celladon Corp, CTI BioPharma Corp, TG Ther Jun 01 2015 
Roth Capital Weighs In On 5 Biotech Stocks to Watch Apr 05 2015 
Cowen & Co Remains Bullish on Celldex Therapeutics Following FDA 'Breakthrough' Approval Feb 24 2015 
CLDX up 223%, Cohen Gains Big Apr 23 2013 
Steve Cohen Increases Celldex Up 145% Apr 06 2013 
5 Resilient Biotech Stocks to Buy for 2012 Feb 28 2012 
CELLDEX THERAPEUTICS, INC (CLDX) CEO Anthony S Marucci buys 12,000 Shares Sep 13 2010 
Weekly CFO Buys Highlight: GNMK, RTIX, BKOR, PTEK, CLDX Sep 12 2010 
CELLDEX THERAPEUTICS, INC Reports Operating Results (10-Q) Aug 05 2010 

More From Other Websites
ETF’s with exposure to Celldex Therapeutics, Inc. : May 24, 2016 May 24 2016
CELLDEX THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial... May 19 2016
8 Stocks on the Move After ASCO Cancer Abstracts May 19 2016
Celldex Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : CLDX-US : May... May 19 2016
Here’s Why These Five Stocks Are Gaining Ground Today May 13 2016
CELLDEX THERAPEUTICS, INC. Financials May 13 2016
ETF’s with exposure to Celldex Therapeutics, Inc. : May 12, 2016 May 12 2016
Celldex Therapeutics, Inc. :CLDX-US: Earnings Analysis: Q1, 2016 By the Numbers May 11 2016
Celldex (CLDX) Posts Wider Q1 Loss, Focus on Pipeline May 06 2016
Celldex Reports First Quarter 2016 Results May 05 2016
CELLDEX THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition,... May 05 2016
Celldex Reports First Quarter 2016 Results May 05 2016
Trending Now: CLDX May 04 2016
Biotech Stocks Earnings Preview: REGN, LGND, ECYT & More May 03 2016
Celldex (CLDX): What's Ahead for the Stock in Q1 Earnings? May 02 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)